Compare PGY & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGY | IMNM |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | N/A | 2020 |
| Metric | PGY | IMNM |
|---|---|---|
| Price | $21.85 | $21.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $39.86 | $31.44 |
| AVG Volume (30 Days) | 2.5M | ★ 2.9M |
| Earning Date | 02-12-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,245,946,000.00 | $9,679,000.00 |
| Revenue This Year | $28.75 | N/A |
| Revenue Next Year | $17.23 | $11.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 28.33 | N/A |
| 52 Week Low | $8.27 | $5.15 |
| 52 Week High | $44.99 | $25.30 |
| Indicator | PGY | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 40.60 | 57.90 |
| Support Level | $22.72 | $19.37 |
| Resistance Level | $24.06 | $22.57 |
| Average True Range (ATR) | 1.31 | 1.48 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 16.63 | 45.30 |
Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.